Quince Therapeutics

(NASDAQ) CRTX

Current PriceN/A

Market CapN/A

Since IPO (2019)-100%

5 Year-100%

1 Year-89%

1 Month+21%

Quince Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

$83.98M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

CRTX News

falling chart man watching computer screen

Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?

David HaenFeb 7, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quince Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Dirk Thye, MD

Website

quincetx.com

Headquarters

South San Francisco, CA 94080, US

CRTX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

77%

Return on Capital

-1%

Return on Assets

-90%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$58.07M

EBITDA

$58.07M

Operating Cash Flow

$41.42M

Capital Expenditure

$352.00K

Free Cash Flow

$41.78M

Cash & ST Invst.

$17.75M

Total Debt

$18.36M

Quince Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$39.46M

-155.3%

EBITDA

$19.34M

-127.4%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$604.00K

-102.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$330.00K

-97.8%

Short Term Debt

$18.03M

N/A

Return on Assets

-89.80%

N/A

Return on Invested Capital

-1.00%

N/A

Free Cash Flow

$10.48M

-166.6%

Operating Cash Flow

$10.48M

-165.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SURFSurface Oncology, Inc.

SURFSurface Oncology, Inc.$1.07-0.93%

ACHLAchilles Therapeutics plc

ACHLAchilles Therapeutics plc$1.48+0.68%

LABPLandos Biopharma, Inc.

LABPLandos Biopharma, Inc.$22.93+0.57%

JBIOJade Biosciences, Inc.

JBIOJade Biosciences, Inc.$23.07+3.38%

RPHMReneo Pharmaceuticals, Inc.

RPHMReneo Pharmaceuticals, Inc.$18.20+952.02%

IGMSIGM Biosciences, Inc.

IGMSIGM Biosciences, Inc.$1.27+0.00%

TCRRTCR2 Therapeutics Inc.

TCRRTCR2 Therapeutics Inc.$1.48+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$12.25-0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$53.79+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.72-0.02%

HTZHertz Global

HTZHertz Global$6.95+0.24%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.55+0.08%

OPENOpendoor Technologies

OPENOpendoor Technologies$5.14-0.08%

WULFTeraWulf

WULFTeraWulf$21.36+0.07%

Questions About CRTX

What is the current price of Quince Therapeutics?

Quince Therapeutics is trading at N/A per share.

What is the 52-week range for Quince Therapeutics?

Over the past 52 weeks, Quince Therapeutics has traded between N/A and N/A.

How much debt does Quince Therapeutics have?

As of the most recent reporting period, Quince Therapeutics reported total debt of $18.47M.

How much cash does Quince Therapeutics have on hand?

Quince Therapeutics reported $5.81M in cash and cash equivalents in its most recent financial results.

What is Quince Therapeutics’s dividend yield?

Quince Therapeutics does not currently have a dividend yield.

Quince Therapeutics

Quince Therapeutics Financials at a Glance

CRTX News

Why Cortexyme's Stock Is Crashing Today

2 Short-Squeeze Candidates That Could Go Parabolic Soon

Down 76%: Is Cortexyme Stock a Bargain?

Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors

Here's Why Cortexyme Is Imploding on Wednesday

Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Quince Therapeutics

CRTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Quince Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CRTX

What is the current price of Quince Therapeutics?

What is the 52-week range for Quince Therapeutics?

How much debt does Quince Therapeutics have?

How much cash does Quince Therapeutics have on hand?

What is Quince Therapeutics’s dividend yield?

Premium Investing Services